Response to Comment on Hong et al. Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease. Diabetes Care 2013;36:1304–1311

We thank Lund and Gong (1) for their letter and for taking an interest in our recent article (2). The following are responses to specific inquiries on the details of the trial. First, we respond to the statement that although our randomized clinical trial (RCT) is probably the first report of cardiovascular (CV) outcomes comparing the long-term effects of glipizide and metformin on the major CV events in type 2 diabetic patients who had a history of coronary artery disease, “several previous …